Mechanistic Studies of Psilocybin in Headache Disorders

Who May Qualify: - Age 21 to 70 (inclusive) - Migraine disease per ICHD-3 criteria (for migraine participants) OR Healthy control patient Exclusion criterion - Unstable medical condition or serious nervous system pathology - Pregnant, breastfeeding, lack of adequate birth control - Psychotic or manic disorder - Substance abuse in the prior 3 months - Use of classic psychedelics (e.g., psilocybin, LSD, mescaline) in the past 6 months - Use of cannabis or other THC products in the prior 2 weeks - Urine toxicology positive to drugs of abuse - The use of triptans (e.g., sumatriptan) or ditans (e.g., lasmiditan) more than twice weekly on average - Use of serotonergic preventive therapies (i.e., taken chronically; amitriptyline, fluoxetine, imipramine, cyproheptadine) in the past 6 weeks - Use of preventive or transitional treatments that produce spikes and waning of symptom relief (e.g., botulinum toxin, calcitonin gene-related peptide system targeting antibodies, peripheral nerve or ganglion blocks, chiropractic manipulation) - History of a bleeding disorder or are currently taking anticoagulants (e.g., warfarin, enoxaparin, dabigatran, apixaban). - Use of non-steroidal anti-inflammatory drugs (NSAIDs; e.g., ibuprofen, naproxen) in the 7 days before PET scan and 7 days after PET scan. Always talk to your doctor about whether this trial is right for you.